Review examines why microsatellite-stable tumors resist immunotherapy
Skip to content
The CRC Digest
◇ RESEARCH
Review examines why microsatellite-stable tumors resist immunotherapy
A systematic review found that mismatch repair-proficient, microsatellite stable tumors remain resistant to immunotherapy due to low neoantigen load, defects in antigen presentation, and Wnt/β-catenin pathway activity that reduce immune recognition and T-cell infiltration. (Molecules)